Evidence map›Paper›PMID 32656161›Full record

ArticleTranslational and clinical pharmacology2020

Pharmacokinetic comparison of two bazedoxifene acetate 20 mg tablet formulations in healthy Korean male volunteers.

Ji-Sun Yeun, Hye-Su Kan, Minyu Lee, Namsick Kim, Tae-Young Oh, Seung-Kwan Nam, Yoon Seok Choi, In Sun Kwon, Jang Hee Hong

Open access · diamondAbstract read
In one paragraph

Article in Translational and clinical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Ji-Sun YeunClinical Trials Center, Chungnam National University Hospital, Daejeon 34134, Korea.ORCID https://orcid.org/0000-0003-2902-8368
Hye-Su KanCenter for Infectious Diseases Control, Korea Centers for Disease Control and Prevention, Cheongju 28159, Korea.ORCID https://orcid.org/0000-0003-3583-7049
Minyu LeeHuons Co., Ltd, Seongnam 13486, Korea.ORCID https://orcid.org/0000-0002-4603-8608
Namsick KimHuons Co., Ltd, Seongnam 13486, Korea.ORCID https://orcid.org/0000-0002-4691-6722
Tae-Young OhHuons Co., Ltd, Seongnam 13486, Korea.ORCID https://orcid.org/0000-0002-8263-5805
Seung-Kwan NamHuons Co., Ltd, Seongnam 13486, Korea.ORCID https://orcid.org/0000-0002-8207-5051
Yoon Seok ChoiHuons Co., Ltd, Seongnam 13486, Korea.ORCID https://orcid.org/0000-0002-5332-6368
In Sun KwonClinical Trials Center, Chungnam National University Hospital, Daejeon 34134, Korea.ORCID https://orcid.org/0000-0002-1723-436X
Jang Hee HongClinical Trials Center, Chungnam National University Hospital, Daejeon 34134, Korea.ORCID https://orcid.org/0000-0002-0623-5455
Huons (South Korea) · KRChungnam National University Hospital · KRChungnam National University · KRKorea Center for Disease Control and Prevention · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bazedoxifene, used as bazedoxifene acetate, is a selective estrogen receptor modulator that selectively affects the uterus, breast tissue, bone metabolism, and lipid metabolism by antagonizing or enhancing estrogens in the estrogen receptor in the tissue. This study was conducted as an open, randomized, two-period, two-treatment, crossover design to compare the pharmacokinetic (PK) characteristics and tolerability of two bazedoxifene tablets when administered to 50 healthy Korean male volunteers. Enrolled subjects were randomly allocated to 2 sequences of a single oral administration of a test drug and a reference drug, or vice versa with a 14-day washout period between the two doses. Serial blood samples were collected over 96 h for PK analysis. Plasma concentration of bazedoxifene was assayed using liquid chromatography-tandem spectrometry mass. Forty-five participants completed the study with no clinically relevant safety issues. The peak concentrations (C

trial registrationClinical Research Information Service Identifier: KCT0003978.

Indexed as

BazedoxifeneBioequivalencePharmacokinetics

Identifiers

PMID32656161
PMCPMC7327186
OpenAlexW3037793142

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.